CDC's Spina Bifida Registry Recompete Scores You on Patients You Already Saw — Before You Write a Word
September 28, 2026 · 7 min read
Granted Research Team · Editorial policy
Most competitive federal announcements reward what you promise to do. A smaller class of announcements rewards what you already did, and the scoring sheet tells you so in advance. CDC-RFA-DD-26-0222, Long-term health outcomes of people living with spina bifida, is squarely in the second class — and applicants who read only the grants.gov summary page will get both the money and the odds wrong.
The NOFO posted August 26, 2026 and closes Monday, October 26, 2026 at 11:59 p.m. ET. The optional letter of intent was due September 26, 2026, which has passed; it was optional, and missing it does not disqualify anyone. CDC held an informational call on September 17, 2026, and posted a recording. Assistance listing: 93.073, Birth Defects and Developmental Disabilities — Prevention and Surveillance. Funding instrument: cooperative agreement, not a grant, which matters more than most applicants expect.
The two components, and why they are not interchangeable
Component A — National Spina Bifida Patient Registry (NSBPR). Collect high-quality longitudinal data on children and adults with spina bifida who receive care in specialized clinics participating in the NSBPR. Expected awards: 8 to 11. Funding per recipient per 12-month budget period: $100,000 to $200,000. Over the full period of performance: $300,000 to $600,000 per recipient.
Component B — UMPIRE. Carry out and evaluate the Urologic Management to Preserve Initial Renal Function protocol — an iterative protocol aimed at managing the urinary and kidney systems of infants and young children with myelomeningocele. Expected awards: 6 to 9. Funding per recipient per budget period: $50,000 to $100,000. Over the period: $150,000 to $300,000.
Period of performance is three years, structured as 12-month budget periods. Expected award date is August 1, 2027; expected start is September 1, 2027. You may apply to either component or both, but each organization — normally identified by a unique UEI — may submit one application per component, for a maximum of two. There is no cost-sharing requirement, and CDC explicitly will not consider voluntary cost share during review. If you commit it anyway, it goes into the award and you have to report on it. Don't volunteer it.
The summary fields are wrong by a factor of three
Here is the trap. The grants.gov synopsis for this opportunity reports total program funding of $3,000,000, an award floor of $100,000, an award ceiling of $300,000, and 19 expected awards. Read those four numbers together and you conclude the program is a $3 million, three-year, 19-award competition — roughly $158,000 per award across the whole period.
The NOFO body says something different. Expected total program funding over the period of performance is $2,400,000 to $6,600,000 for Component A and $900,000 to $2,700,000 for Component B — a combined $3.3 million to $9.3 million.
The reconciliation is arithmetic. At the top of every range, a single 12-month budget period costs CDC 11 × $200,000 + 9 × $100,000 = $3.1 million. The $3,000,000 in the synopsis field is a first-year obligation figure, not a program total. The $300,000 ceiling is Component A's three-year per-applicant maximum, and the $100,000 floor is Component A's annual minimum. The summary fields mix annual and multi-year units in a single table.
Two practical consequences. First, build your budget from the NOFO's per-budget-period bands, not the synopsis ceiling, or you will under-request by two-thirds and then find yourself with a three-year workplan funded like a one-year pilot. Second, the synopsis's "19 expected awards" is the midpoint of 8–11 plus 6–9; the honest range is 14 to 20 awards, and CDC states plainly that the number is subject to available funds and program priorities.
The eligibility list is broad. The responsiveness criteria are not.
On paper, almost anyone can apply: state, county, city and township governments, special districts, independent school districts, public and private institutions of higher education, federally recognized tribal governments and other tribal organizations, housing authorities, nonprofits with and without 501(c)(3) status, for-profit organizations, small businesses, and bona fide agents applying on behalf of government entities.
Then the responsiveness criteria arrive, and they are not about organization type at all. Every applicant must submit a document labeled "Responsiveness criteria" for each component.
For Component A, that document must state the number of patients currently enrolled in NSBPR with at least one registry visit between January 2020 and August 2024 carrying one of six diagnoses — myelomeningocele, meningocele, lipomyelomeningocele, fatty/thickened filum, split cord malformation, or terminal myelocystocele. It must also report the proportion of those individuals with more than five visits, and include at least one letter of commitment from the participating clinic or hospital system documenting access to patients with spina bifida and collection of NSBPR data elements.
For Component B, it must state the number of patients previously enrolled in UMPIRE with a myelomeningocele diagnosis and at least one visit in that same January 2020–August 2024 window, include the curriculum vitae of a pediatric urologist on the study team, and include an equivalent letter of commitment.
Read that again: the responsiveness gate references patient counts already in CDC's registry and a data window that closed in August 2024. A for-profit data firm and a small business are both technically eligible; neither can manufacture a 2020–2024 registry cohort in the five weeks before the deadline. The eligibility table describes who may submit. The responsiveness document describes who can compete.
Twenty of forty approach points are historical volume
The scoring makes the same point with numbers. Both components allocate 40 points to the approach, 25 to the evaluation and performance measurement plan, and 35 to organizational capacity.
Inside Component A's 40-point approach:
| Criterion | Points |
|---|---|
| Clear background problem and how the application addresses it | 2 |
| Strategies, activities, outcomes consistent with the program logic model | 3 |
| Demonstrated ability and experience collecting longitudinal SB data | 4 |
| Individuals seen 2020–2024 (≥300 = 10; 200 = 6; 100 = 3) | 10 |
| Proportion with more than five visits (≥50% = 10; 25% = 5; <5% = 1) | 10 |
| Population distribution by age and race/ethnicity | 2 |
| Adherence to CDC's required data system and secure transfer capability | 4 |
| Work plan alignment with approach and CDC's prescribed format | 5 |
Half of Component A's approach score — 20 of 40 points — is a look-up from your own chart counts. A site with 300 patients and 50% high-frequency follow-up banks 20 points before writing a sentence. A site with 100 patients and 25% follow-up banks 8. That 12-point spread is larger than any narrative section in the entire approach.
Component B is structured the same way, more bluntly: 12 points for demonstrating at least 20 individuals with myelomeningocele whose clinical data was recorded between 2020 and 2024, plus 8 points for longitudinal data experience. That is half of Component B's approach score, again anchored on a closed historical window.
One escape hatch is written into the scoring note for Component A: more than one clinic — smaller clinics, pediatric or adult clinics — can join and apply to this NOFO as one organization. If your center has 150 registry patients, the highest-leverage move available in the remaining weeks is not a better narrative. It is finding a second clinic with 150 more and submitting as one applicant. A combination that crosses 300 converts a 3-point line into a 10-point line and does the same arithmetic on the five-visit proportion.
What the remaining weeks are actually for
The 35-point organizational capacity section names specific staff. Component A wants a data coordinator with described capacity to support data management and timely submission to CDC, and a data analyst with described capacity to support research analyses. Both components award 10 points for relevant management, administrative, and technical experience, 10 for experience or capacity to implement the evaluation plan, 8 for a staffing plan with clearly defined roles, 2 for an organizational chart that supports the structure, and 5 for collaborations that add value.
Named roles in a scoring table are an instruction. If the data coordinator and data analyst are unnamed TBDs in your staffing plan, you are conceding points that cost nothing to secure — an internal reassignment with a resume and a job description satisfies the criterion.
The cooperative-agreement instrument is the last thing worth internalizing. CDC will be substantially involved: the announcement requires adherence to a CDC-specified data system, secure transfer of limited-identifier data to CDC for quality checks and pooling, and a work plan "consistent with the content and format proposed by CDC." This is not a program where you design your own instrument and report annually. Applicants who have run NCBDDD cooperative agreements before will find this familiar; applicants coming from investigator-initiated R01 culture should budget staff time for CDC-directed data operations rather than for independent analysis.
For readers tracking the wider CDC picture, this NOFO lands in the same stretch as the agency's state biomonitoring cooperative agreement forecast and NIH's children's environmental health center recompete — three surveillance-infrastructure competitions in a single month, all of them scoring incumbency in one form or another.
The deadline is October 26, 2026. If your site is already in the NSBPR, the work between now and then is arithmetic, letters of commitment, and named staff. If it isn't, the honest read is that this cycle rewards a partnership, not a solo application.